These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38581761)

  • 1. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
    Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
    Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of non-lymphoid immune cells of the tumor microenvironment, including neutrophils, eosinophils, and mast cells in breast carcinomas.
    Okcu O; Öztürk Ç; Şen B; Ayazoğlu MS; Güvendi GF; Öztürk SD; Aşkan G; Bedir R
    Ann Diagn Pathol; 2023 Aug; 65():152151. PubMed ID: 37121083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of stromal tumor-infiltrating lymphocytes in neoadjuvant chemotherapy for invasive breast carcinoma: Predictive insights across molecular subtypes.
    Khan AA; Ahuja S; Kiruthikasri K; Zaheer S
    Pathol Res Pract; 2024 Aug; 260():155382. PubMed ID: 38850879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
    Liu K; Zhao K; Wang L; Sun E
    Pathol Res Pract; 2018 Aug; 214(8):1074-1080. PubMed ID: 29803657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
    Kashiwagi S; Asano Y; Takada K; Goto W; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    Anticancer Res; 2022 Mar; 42(3):1421-1431. PubMed ID: 35220235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
    Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV
    Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
    Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
    Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Mao Y; Qu Q; Zhang Y; Liu J; Chen X; Shen K
    PLoS One; 2014; 9(12):e115103. PubMed ID: 25501357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
    Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
    Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.
    Chin K; Landén AH; Kovács A; Wärnberg F; Ekholm M; Karlsson P; Olofsson Bagge R
    Breast Cancer Res Treat; 2024 Aug; 207(1):49-63. PubMed ID: 38703286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.